Literature DB >> 29436118

Cortistatin inhibits arterial calcification in rats via GSK3β/β-catenin and protein kinase C signalling but not c-Jun N-terminal kinase signalling.

Y Liu1, F Lin2, Y Fu1, W Chen1, W Liu1, J Chi1, X Zhang1, X Yin1.   

Abstract

AIM: Cortistatin (CST) is a newly discovered endogenous active peptide that exerts protective effects on the cardiovascular system. However, the relationship between CST and aortic calcification and the underlying mechanism remain obscure. Therefore, we investigated effects of CST on aortic calcification and its signalling pathways.
METHODS: Calcium content and alkaline phosphatase (ALP) activity were measured using the o-cresolphthalein colorimetric method and ALP assay kit respectively. Protein expression of smooth muscle (SM)-ɑ-actin, osteocalcin (OCN), β-catenin, glycogen synthase kinase 3β (GSK3β), p-GSK3β, protein kinase C (PKC), p-PKC, c-Jun N-terminal kinase (JNK) and p-JNK was determined using Western blotting.
RESULTS: In aorta from a rat vitamin D3 calcification model, CST abrogated calcium deposition and pathological damage, decreased the protein expression of OCN and β-catenin and increased SM-ɑ-actin expression. In a rat cultured vascular smooth muscular cell (VSMC) calcification model induced by β-glycerophosphate (β-GP), CST inhibited the increase in ALP activity, calcium content and OCN protein and the decrease in SM-α-actin expression. CST also inhibited the β-GP-induced increase in p-GSK3β and β-catenin protein (both P < .05). The inhibitory effects of CST on ALP activity, calcium deposition and β-catenin protein were abolished by pretreatment with lithium chloride, a GSK3β inhibitor. CST promoted the protein expression of p-PKC by 68.5% (P < .01), but not p-JNK. The ability of CST to attenuate β-GP-induced increase in ALP activity, calcium content and OCN expression in the VSMC model was abolished by pretreatment with the PKC inhibitor Go6976.
CONCLUSION: These results indicate that CST inhibits aortic calcification and osteogenic differentiation of VSMCs likely via the GSK3β/β-catenin and PKC signalling pathways, but not JNK signalling pathway.
© 2018 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Wnt signalling pathway; aortic calcification; cortistatin; vascular smooth muscular cells

Mesh:

Substances:

Year:  2018        PMID: 29436118     DOI: 10.1111/apha.13055

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  5 in total

1.  Salusin-β Promotes Vascular Calcification via Nicotinamide Adenine Dinucleotide Phosphate/Reactive Oxygen Species-Mediated Klotho Downregulation.

Authors:  Haijian Sun; Feng Zhang; Yu Xu; Shuo Sun; Huiping Wang; Qiong Du; Chenxin Gu; Stephen M Black; Ying Han; Haiyang Tang
Journal:  Antioxid Redox Signal       Date:  2019-12-20       Impact factor: 8.401

2.  CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway.

Authors:  Jia-Hui Gao; Lin-Hao He; Xiao-Hua Yu; Zhen-Wang Zhao; Gang Wang; Jin Zou; Feng-Jiao Wen; Li Zhou; Xiang-Jun Wan; Da-Wei Zhang; Chao-Ke Tang
Journal:  J Lipid Res       Date:  2019-10-29       Impact factor: 5.922

3.  Cortistatin exerts antiproliferation and antimigration effects in vascular smooth muscle cells stimulated by Ang II through suppressing ERK1/2, p38 MAPK, JNK and ERK5 signaling pathways.

Authors:  Ying Wang; Xin Zhang; Lei Gao; Jihe Li; Wenjia Chen; Jinyu Chi; Xiaohui Zhang; Yu Fu; Meng Zhao; Na Liu; Yang Li; Yang Xu; Kelaier Yang; Xinhua Yin; Yue Liu
Journal:  Ann Transl Med       Date:  2019-10

Review 4.  Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases.

Authors:  Yao Chen; Yongfen Qi; Weiwei Lu
Journal:  Oxid Med Cell Longev       Date:  2022-10-03       Impact factor: 7.310

5.  Cardioprotection of cortistatin against isoproterenol-induced myocardial injury in rats.

Authors:  Wenjia Chen; Juan Liang; Yu Fu; Yuanyuan Jin; Runan Yan; Jinyu Chi; Wenxiu Liu; Yue Liu; Xinhua Yin
Journal:  Ann Transl Med       Date:  2020-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.